2-y overall survival rates of study cohorts
| . | ALFA (N = 471) . | AMLSG (N = 223) . | SAL (N = 466) . | HdF (N = 141) . | MDACC DNT (N = 248) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | |
| Go-go | 184 (39.1) | 66.1 | 84 (37.7) | 44.8 | 171 (36.7) | 35.5 | 44 (31.2) | 43.4 | 77 (31) | 57 |
| Slow-go | 251 (53.3) | 39.1 | 113 (50.7) | 21.9 | 243 (52.1) | 28.2 | 78 (55.3) | 29.9 | 95 (38) | 24.3 |
| No-go | 36 (7.6) | 2.8 | 26 (11.6) | 3.8 | 52 (11.2) | 2 | 19 (13.5) | 10.5 | 76 (31) | 3.4 |
| . | ALFA (N = 471) . | AMLSG (N = 223) . | SAL (N = 466) . | HdF (N = 141) . | MDACC DNT (N = 248) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | N (%) . | 2-y OS % . | |
| Go-go | 184 (39.1) | 66.1 | 84 (37.7) | 44.8 | 171 (36.7) | 35.5 | 44 (31.2) | 43.4 | 77 (31) | 57 |
| Slow-go | 251 (53.3) | 39.1 | 113 (50.7) | 21.9 | 243 (52.1) | 28.2 | 78 (55.3) | 29.9 | 95 (38) | 24.3 |
| No-go | 36 (7.6) | 2.8 | 26 (11.6) | 3.8 | 52 (11.2) | 2 | 19 (13.5) | 10.5 | 76 (31) | 3.4 |
AMLSG, AML Study Group; HdF-Hauts-de-France; MDACC, MD Anderson Cancer Center; SAL, Study Alliance Leukemia group.